Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Pyruvate kinase activators for the treatment of thalassemia

Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses the possibility of using pyruvate kinase activators for the treatment of patients with thalassemia. These agents are used to treat pyruvate kinase deficiency, but recent trials provide evidence for their efficacy in the treatment of thalassemia. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.